SynthesisPloS one2020
Retention of patients in opioid substitution treatment: A systematic review.
Synthesis in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07148206 (Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial), which is not on this map. Cited by 151 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial
Who cites it
151 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Barriers and facilitators to detoxification from opioid substitution treatment: A mixed-methods systematic review.Addiction (Abingdon, England) · 2026Pooled it
- Extended-release pharmacotherapies for substance use disorders in incarcerated populations: A systematic review.Addiction (Abingdon, England) · 2025Pooled it
- Patient experience of opioid use disorder treatment medications: a systematic review of contemporary qualitative research.BMJ open · 2024Pooled it
- Patient's and healthcare provider's experiences with Opioid Maintenance Treatment (OMT): a qualitative evidence synthesis.BMC health services research · 2024Pooled it
- The impact of relaxing restrictions on take-home doses during the COVID-19 pandemic on program effectiveness and client experiences in opioid agonist treatment: a mixed methods systematic review.Substance abuse treatment, prevention, and policy · 2023Pooled it
- Mindful moms: acceptability and impact of co-designed and digitally delivered video meditations for pregnant and parenting women with opioid use disorder.Annals of medicine · 2025Trial
- Non-adherence to treatment and concurrent opioid use among people on methadone maintenance treatment using methamphetamine in Vietnam.Journal of substance use and addiction treatment · 2025Trial
- Opioid agonist treatment outcomes among individuals with a history of nonfatal overdose: Findings from a pragmatic, pan-Canadian, randomized control trial.The American journal on addictions · 2025Trial
- Does implementation of office based addiction treatment by a nurse care manager increase the duration of OUD treatment in primary care? A secondary analysis of the PROUD randomized control trial.Drug and alcohol dependence · 2024Trial
- Associations Between Buprenorphine\Naloxone and Methadone Treatment and non-Opioid Substance Use in Prescription-Type Opioid Use Disorder: Secondary Analyses From the OPTIMA Study: Associations entre le traitement avec la buprénorphine/naloxone et avec la méthadone et l'utilisation de substances non opioïdes dans le trouble lié à l'usage d'opioïdes de type sur ordonnance : analyses secondaires de l'étude OPTIMA.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2024Trial
- Opioid agonist therapy switching among individuals with prescription-type opioid use disorder: Secondary analysis of a pragmatic randomized trial.Drug and alcohol dependence · 2023Trial
- Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder.Substance abuse treatment, prevention, and policy · 2022Trial
- Impact of fentanyl use on initiation and discontinuation of methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: secondary analysis of a Canadian treatment trial.Addiction (Abingdon, England) · 2022Trial
- Correlates of days of medication for opioid use disorder exposure among people living with HIV in Northern Vietnam.The International journal on drug policy · 2022Trial
- Associations between fentanyl use and initiation, persistence, and retention on medications for opioid use disorder among people living with uncontrolled HIV disease.Drug and alcohol dependence · 2021Trial
- Factors associated with obtaining employment among opioid use disorder patients enrolled in a therapeutic workplace intervention.Drug and alcohol dependence · 2021Trial
- Would we, could we? Measuring attitudinal and capacity barriers to supporting recovery housing residents on medication for opioid use disorder.Journal of substance use and addiction treatment · 2026Article
- Trait impulsivity prospectively predicts lower methadone treatment retention: moderation by pain catastrophizing.Addiction science & clinical practice · 2026Observational
- Influence of residential greenness and season on discontinuation of medication treatment for opioid use disorder across rural to urban community types.Addictive behaviors reports · 2026Article
- The Hepatitis C Cascade of Care for Opioid Agonist Therapy Recipients in Australia.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
91 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRetention in opioid substitution (OST) treatment is associated with substantial reductions in all cause and overdose mortality. This systematic review aims to identify both protective factors supporting retention in OST, and risk factors for treatment dropout.
methodsA systematic search was performed using MEDLINE, Embase, PsycInfo, CINAHL and Web of Science (January 2001 to October 2019). Randomised controlled trials (RCTs) and observational cohort studies reporting on retention rates and factors associated with retention in OST were included. Factors associated with treatment retention and dropout were explored according to the Maudsley Addiction Profile. A narrative synthesis is provided.
results67 studies were included in this review (4 RCTs and 63 observational cohort studies; N = 294,592), all assessing factors associated with retention in OST or treatment dropout. The median retention rate across observational studies was approximately 57% at 12 months, which fell to 38.4% at three years. Studies included were heterogeneous in nature with respect to treatment setting, type of OST, risk factor assessment, ascertainment of outcome and duration of follow-up. While the presence of such methodological heterogeneity makes it difficult to synthesise results, there is limited evidence to support the influence of a number of factors on retention, including age, substance use, OST drug dose, legal issues, and attitudes to OST.
conclusionsYounger age, substance use particularly cocaine and heroin use, lower doses of methadone, criminal activity/incarceration, and negative attitudes to MMT appear to be associated with reduced retention in OST. A consensus definition of retention is required to allow for comparability across future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.